AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting, Business News – AsiaOne
SUZHOU, China and ROCKVILLE, Md. , Oct. 20, 2022 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release results from the Phase I first-in-human study of APG-1387, the company’s investigational inhibitor of apoptosis protein (IAP)…
Read More
0
